1033 related articles for article (PubMed ID: 20844345)
61. Hydration requirements in patients receiving highly emetogenic chemotherapy.
Erickson R; Nebughr N; Mosier MC; Nibley W
Future Oncol; 2019 Mar; 15(7):753-761. PubMed ID: 30499739
[TBL] [Abstract][Full Text] [Related]
62. Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron?
Doggrell SA
Expert Opin Pharmacother; 2017 Jul; 18(10):1019-1026. PubMed ID: 28612633
[TBL] [Abstract][Full Text] [Related]
63. Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter.
Zoto T; Kilickap S; Yasar U; Celik I; Bozkurt A; Babaoglu MO
Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):354-60. PubMed ID: 25286968
[TBL] [Abstract][Full Text] [Related]
64. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
Schwartzberg LS
Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
[TBL] [Abstract][Full Text] [Related]
65. A narrative review of tropisetron and palonosetron for the control of chemotherapy-induced nausea and vomiting.
Yang Y; Zhang L
Chin Clin Oncol; 2020 Apr; 9(2):17. PubMed ID: 31865713
[TBL] [Abstract][Full Text] [Related]
66. Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
Hsu YC; Chen CY; Tam KW; Hsu CY
Eur J Clin Pharmacol; 2021 Nov; 77(11):1597-1609. PubMed ID: 33993343
[TBL] [Abstract][Full Text] [Related]
67. Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.
Tan M
Expert Opin Pharmacother; 2003 Sep; 4(9):1563-71. PubMed ID: 12943486
[TBL] [Abstract][Full Text] [Related]
68. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis.
Tricco AC; Blondal E; Veroniki AA; Soobiah C; Vafaei A; Ivory J; Strifler L; Cardoso R; Reynen E; Nincic V; Ashoor H; Ho J; Ng C; Johnson C; Lillie E; Antony J; Roberts DJ; Hemmelgarn BR; Straus SE
BMC Med; 2016 Dec; 14(1):216. PubMed ID: 28007031
[TBL] [Abstract][Full Text] [Related]
69. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Morrow GR; Hickok JT; Rosenthal SN
Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113
[TBL] [Abstract][Full Text] [Related]
70. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
Aapro M; Johnson J
Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
[TBL] [Abstract][Full Text] [Related]
71. An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
Fabi A; Malaguti P
Expert Opin Pharmacother; 2013 Apr; 14(5):629-41. PubMed ID: 23414148
[TBL] [Abstract][Full Text] [Related]
72. Genetic polymorphisms in the three malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy.
Hassan BA; Yusoff ZB
Asian Pac J Cancer Prev; 2011; 12(1):185-91. PubMed ID: 21517255
[TBL] [Abstract][Full Text] [Related]
73. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Simino GP; Marra LP; Andrade EI; Acúrcio Fde A; Reis IA; De Araújo VE; Cherchiglia ML
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1183-94. PubMed ID: 27180992
[TBL] [Abstract][Full Text] [Related]
74. [Nausea and vomiting].
Fujii M
Nihon Rinsho; 2003 Jun; 61(6):954-8. PubMed ID: 12806942
[TBL] [Abstract][Full Text] [Related]
75. The next generation of chemotherapy-induced nausea and vomiting prevention and control: a new 5-HT3 antagonist arrives.
Rittenberg CN
Clin J Oncol Nurs; 2004 Jun; 8(3):307-8, 310. PubMed ID: 15208825
[TBL] [Abstract][Full Text] [Related]
76. Recent Advances in Antiemetics: New Formulations of 5-HT3 Receptor Antagonists in Adults.
Smith C; Smith M; Cunningham R; Davis S
Cancer Nurs; 2020; 43(4):E217-E228. PubMed ID: 30688665
[TBL] [Abstract][Full Text] [Related]
77. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
Balfour JA; Goa KL
Drugs; 1997 Aug; 54(2):273-98. PubMed ID: 9257083
[TBL] [Abstract][Full Text] [Related]
78. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP
J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671
[TBL] [Abstract][Full Text] [Related]
79. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
Botrel TE; Clark OA; Clark L; Paladini L; Faleiros E; Pegoretti B
Support Care Cancer; 2011 Jun; 19(6):823-32. PubMed ID: 20495832
[TBL] [Abstract][Full Text] [Related]
80. Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced - nausea and vomiting.
Spartinou A; Nyktari V; Papaioannou A
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1289-1297. PubMed ID: 29057666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
